Furthermore, ERG overexpression is itself insufficient for prostate cancer initiation and ERG gene fusions often co-occur with loss of function alterations to PTEN/TP53 in both primary and metastatic prostate cancer. This evidence concerns the gene ERG and metastatic prostate carcinoma.